Clinical Trials Directory

Trials / Completed

CompletedNCT01146548

Fluoxetine in Multiple System Atrophy Patients

Assessment of Fluoxetine's Effect in Patients With Multiple System Atrophy : a Double Blind Placebo-controlled Randomized Trial

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
87 (actual)
Sponsor
University Hospital, Toulouse · Academic / Other
Sex
All
Age
30 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This is a French national trial, conducted using a double-blind, placebo-controlled, randomised design involving 15 centers and 88 patients of both sexes. The primary objective of the trial is to evaluate the effect of a selective inhibitor of serotonin reuptake, the Fluoxétine, at a higher dose (40 mg/day) than usually recommended for depressed patients, after three months in patients suffering from an atypical Parkinson's disease called Multiple System Atrophy, compared to the placebo effect. Secondary objectives of the trial are the evaluation of the effects of Fluoxétine after six weeks at the dose of 20 mg/day, after six months at the dose of 40mg/day, and assess the effects on mortality, quality of life, autonomic disorders, particularly orthostatic hypotension, mood and others symptoms such as sleep, apathy, pain and fatigue.

Detailed description

Fluoxetine is first introduced in dose of 20 mg/day and after six weeks the dose is increased to 40 mg/day. If patients have side effects at the dose of 40 mg/day, the dose may be reduced at 20 mg/day. Assessment visits will be conducted at 6 weeks, 3 months, and 6 months of treatment. After 6 months, trial's treatment with fluoxetine is discontinued gradually. A new assessment will be conducted one month after the end of treatment. The expected results are the demonstration of improved scores of the scale UMSARS after 3 and 6 months in the fluoxetine group compared to the placebo group.

Conditions

Interventions

TypeNameDescription
DRUGFLUOXETINE20mg/d, oral administration for 6 weeks, then 40mg/d for 4 months.

Timeline

Start date
2008-05-01
Primary completion
2011-06-01
Completion
2011-09-01
First posted
2010-06-17
Last updated
2015-03-26

Locations

14 sites across 1 country: France

Source: ClinicalTrials.gov record NCT01146548. Inclusion in this directory is not an endorsement.